Published in Oncology on January 01, 1985
Functional brain mapping by blood oxygenation level-dependent contrast magnetic resonance imaging. A comparison of signal characteristics with a biophysical model. Biophys J (1993) 6.52
Dissociating pain from its anticipation in the human brain. Science (1999) 4.36
Experimental determination of the BOLD field strength dependence in vessels and tissue. Magn Reson Med (1997) 2.13
An fMRI study of the selective activation of human extrastriate form vision areas by radial and concentric gratings. Curr Biol (2000) 2.07
Neural correlates of traumatic memories in posttraumatic stress disorder: a functional MRI investigation. Am J Psychiatry (2001) 1.92
Environmental estrogen stimulation of growth and estrogen receptor function in preneoplastic and cancerous human breast cell lines. J Natl Cancer Inst (1997) 1.88
Cerebral cortical representation of automatic and volitional swallowing in humans. J Neurophysiol (2001) 1.63
A comparison of frontoparietal fMRI activation during anti-saccades and anti-pointing. J Neurophysiol (2000) 1.51
On the characteristics of functional magnetic resonance imaging of the brain. Annu Rev Biophys Biomol Struct (1998) 1.44
Comparison of the quantification precision of human short echo time (1)H spectroscopy at 1.5 and 4.0 Tesla. Magn Reson Med (2000) 1.37
Brief visual stimulation allows mapping of ocular dominance in visual cortex using fMRI. Hum Brain Mapp (2001) 1.37
Distinguishing subregions of the human MT+ complex using visual fields and pursuit eye movements. J Neurophysiol (2001) 1.37
Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. Prostate (1999) 1.26
Motor area activity during mental rotation studied by time-resolved single-trial fMRI. J Cogn Neurosci (2000) 1.23
In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep (1978) 1.15
Eye position signal modulates a human parietal pointing region during memory-guided movements. J Neurosci (2000) 1.14
BOLD fMRI response of early visual areas to perceived contrast in human amblyopia. J Neurophysiol (2000) 1.12
Human forebrain activation by visceral stimuli. J Comp Neurol (1999) 1.10
A transmit-only/receive-only (TORO) RF system for high-field MRI/MRS applications. Magn Reson Med (2000) 1.10
A prospective study of cognitive impairment in ALS. Neurology (1999) 1.08
Spectroscopic lineshape correction by QUECC: combined QUALITY deconvolution and eddy current correction. Magn Reson Med (2000) 1.07
Comparison of memory- and visually guided saccades using event-related fMRI. J Neurophysiol (2003) 1.05
The effects of visual object priming on brain activation before and after recognition. Curr Biol (2000) 1.05
Functional imaging of human motor cortex at high magnetic field. J Neurophysiol (1993) 1.03
31P magnetic resonance spectroscopy of the Sherpa heart: a phosphocreatine/adenosine triphosphate signature of metabolic defense against hypobaric hypoxia. Proc Natl Acad Sci U S A (1996) 0.99
Functional MRI of oropharyngeal air-pulse stimulation. Neuroscience (2008) 0.97
Perirhinal and hippocampal contributions to visual recognition memory can be distinguished from those of occipito-temporal structures based on conscious awareness of prior occurrence. Hippocampus (2007) 0.96
Amplitude response and stimulus presentation frequency response of human primary visual cortex using BOLD EPI at 4 T. Magn Reson Med (1998) 0.94
Recovery of fMRI activation in motion area MT following storage of the motion aftereffect. J Neurophysiol (1999) 0.92
Absence of IgA nephropathy in patients with ankylosing spondylitis. Rheumatol Int (1986) 0.91
Spectroscopic imaging of circular voxels with a two-dimensional Fourier-series window technique. J Magn Reson B (1994) 0.91
Induced resistance in leukaemia L1210 to adriamycin and its cross-resistance to vincristine and bouvardin. Chemotherapy (1982) 0.88
Differences in perceived shape from shading correlate with activity in early visual areas. Curr Biol (1997) 0.86
In vivo anti-cancer activity of RC-18: a plant isolate from Rubia cordifolia, Linn. against a spectrum of experimental tumour models. Chemotherapy (1982) 0.86
Strongyloides stercoralis associated with a bleeding gastric ulcer. Gut (1990) 0.83
Anti-tumour activity of the extract of Semecarpus anacardium L. nuts in experimental tumor models. Indian J Exp Biol (1980) 0.82
Synthesis, characterization, and cytotoxic studies of alpha-diimine/1,2-diamine platinum(II) and palladium(II) complexes of selenite and tellurite and binding of some of these complexes to DNA. J Inorg Biochem (1991) 0.82
Combination chemotherapy of early and advanced murine P388 leukaemia with bouvardin, cis-diamminedichloroplatinum and vincristine. Oncology (1984) 0.81
Anergic T lymphocytes selectively express an integrin regulatory protein of the cytohesin family. J Immunol (2000) 0.81
Synthesis, spectroscopic, cytotoxic, and DNA binding studies of binuclear 2,2'-bipyridine-platinum(II) and -palladium(II) complexes of meso-alpha,alpha'-diaminoadipic and meso-alpha,alpha'-diaminosuberic acids. J Inorg Biochem (1992) 0.80
Comparison of multiecho postprocessing schemes for SWI with use of linear and nonlinear mask functions. AJNR Am J Neuroradiol (2013) 0.80
Reduced visual evoked responses in multiple sclerosis patients with optic neuritis: comparison of functional magnetic resonance imaging and visual evoked potentials. Mult Scler (1999) 0.80
Synthesis and spectroscopic studies of potential anticancer [platinum(II)(2,2'-bipyridine)(amino acid)]n+ (n = 1 or 2) complexes. J Inorg Biochem (1985) 0.80
Effect of luminance contrast on BOLD fMRI response in human primary visual areas. J Neurophysiol (1998) 0.80
Syntheses and spectroscopic studies of potential antitumor copper(II) complexes with 5-phenylazo-3-methoxy salicylidene thiosemicarbazone and N4 substituted thiosemicarbazones. J Inorg Biochem (1989) 0.79
Cancer of the urinary bladder category T2, T3, (NxMo) treated by interstitial radium implant: second report. Int J Radiat Oncol Biol Phys (1983) 0.78
In vitro enhancement of adriamycin cytotoxicity in human myeloid leukemia cells exposed to verapamil. Oncology (1984) 0.78
Synergistic antitumor activity of cisplatin and interleukin 1 in sensitive and resistant solid tumors. Cancer Res (1993) 0.78
Some potential antitumor 2,2'-dipyridylamine Pt(II)/Pd(II) complexes with amino acids: their synthesis, spectroscopy, DNA binding, and cytotoxic studies. J Inorg Biochem (1993) 0.78
The functional scout image: immediate mapping of cortical function at 4 Tesla using receiver phase cycling. Magn Reson Med (1997) 0.77
Repetition priming and the time course of object recognition: an fMRI study. Neuroreport (1999) 0.77
Cytotoxicity and DNA binding studies of several platinum (II) and palladium (II) complexes of the 2,2'-bipyridine and an anion of 2-pyridinecarboxylic/2-pyrazinecarboxylic acid. J Inorg Biochem (1992) 0.77
Circumvention of adriamycin resistance: effect of 2-methyl-1,4-naphthoquinone (vitamin K3) on drug cytotoxicity in sensitive and MDR P388 leukemia cells. Cancer Lett (1992) 0.77
Some potential anticancer palladium(II) complexes of 2,2'-bipyridine and amino acids. J Inorg Biochem (1986) 0.77
Radiometric evaluation of antibacterial activity of bouvardin (NSC 259968) on Escherichia coli and Staphylococcus aureus. Indian J Exp Biol (1986) 0.77
Some mixed-ligand palladium(II) complexes of 2,2'-bipyridine and amino acids as potential anticancer agents. J Inorg Biochem (1985) 0.77
Enhancement of the in vitro cytotoxicity of bouvardin by verapamil alone and combined with hyperthermia in Sarcoma 180 and Ehrlich ascites carcinoma cells. J Cancer Res Clin Oncol (1986) 0.77
Effect of bouvardin (NSC 259968) on the growth characteristics an nucleic acids and protein syntheses profiles of P388 leukemia cells. Chemotherapy (1981) 0.76
Effect of alterations in permeability by nonionic surfactants on adriamycin cytotoxicity in murine tumor models in vitro. Oncology (1990) 0.76
Synthesis, characterization, DNA binding, and cytotoxic studies of some mixed-ligand palladium(II) and platinum(II) complexes of alpha-diimine and amino acids. J Inorg Biochem (1991) 0.76
Synthesis, characterization, cytotoxic, and DNA binding studies of some platinum (II) complexes of 1,2-diamine and alpha-diimine with 2-pyridinecarboxylate anion. J Inorg Biochem (1996) 0.76
Acute fatal leukoencephalopathy after interleukin-2 therapy. N Engl J Med (1990) 0.75
Letter: Reaction to acetaminophen. Can Med Assoc J (1974) 0.75
Anti-tumour activity of the methanol extract Ervatamia heyneana (NSC B668619). Indian J Exp Biol (1979) 0.75
Effect of RC-18, a new anticancer principle isolated from Rubia cordifolia, Linn. on cell cycle of P388 tumour system. Biomed Pharmacother (1982) 0.75
Studies on high-dose chemotherapy of amygdalin in murine P388 lymphocytic leukaemia and P815 mast cell leukaemia. J Cancer Res Clin Oncol (1985) 0.75
Effect of Tween 80 on adriamycin cytotoxicity in murine P388 leukemia. Tumori (1984) 0.75
Toxicological study of Semecarpus anacardium nut extract. Indian J Physiol Pharmacol (1979) 0.75
Potentiation of hydroxyurea cytotoxicity by iron-chelating agent in murine tumor models in vitro. Cancer Drug Deliv (1986) 0.75
Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells by dipyrone. Oncology (1987) 0.75
Augmentation of hydroxyurea cytotoxicity by sintamil in human chronic myeloid leukemia cells. Tumori (1986) 0.75
Microbiological assay for antifolate using folic acid assay method. Indian J Cancer (1979) 0.75
Modification of tumor cell sensitivity to antineoplastic agents lonidamine and bouvardin (NSC 259968) at elevated temperatures. Neoplasma (1986) 0.75
Reversal of natural resistance to bouvardin (NSC 259968) in sarcoma 180 cells in vitro and in vivo by verapamil. J Cancer Res Clin Oncol (1985) 0.75
Effect of bouvardin (BVD, NSC 259968) a prospective anti-tumour agent on host immune response in mice. Indian J Exp Biol (1980) 0.75
Antitumour activity of SAN-AB: an extract of marking nut, Semecarpus anacardium. Indian J Exp Biol (1971) 0.75
Modified combination chemotherapy of leukemia. An attempt to overcome drug resistance. Oncology (1983) 0.75
Effect of mitoxantrone on human chronic myeloid leukemia cells in vitro, combined with hyperthermia. Neoplasma (1986) 0.75
Modulation of in vitro response to adriamycin by verapamil in murine P388 leukaemia, Ehrlich ascites carcinoma and sarcoma 180. Eur J Cancer Clin Oncol (1987) 0.75
Murine splenocyte migration inhibition assay. II. Characterization of splenic suppressor cells in mice bearing P388/ADR tumor. Neoplasma (1983) 0.75
Potentiation of hydroxyurea cytotoxicity in human chronic myeloid leukemia cells by iron-chelating agent. Leuk Res (1986) 0.75
Proteinuria in the Fischer rat by feeding 2-aminoanthraquinone. Med Biol (1980) 0.75
Differential agglutination of P388 adriamycin-sensitive and P388 adriamycin-resistant leukemia cells. Oncology (1983) 0.75
Biochemical parameters of resistance of an adriamycin-resistant subline of P388 leukemia to emetine, an inhibitor of protein synthesis. J Natl Cancer Inst (1978) 0.75
Restoration of drug sensitivity by nitroxazepine hydrochloride in P388 murine leukemia cells resistant to adriamycin. Cancer Drug Deliv (1987) 0.75
Anti-cancer activity of the extracts of Rubia cordifolia Linn. (NSC b668893). Indian J Exp Biol (1980) 0.75
Anti-cancer activity of the extracts of stem and leaf of Tylophora indica. Indian J Med Res (1972) 0.75
Tumorigenicity and anti-cancer properties of n-hydroxy urethan. Indian J Cancer (1974) 0.75
Pathology of soft tissue sarcomas. An introduction. J Belge Radiol (1992) 0.75
Effect of vitamin A compounds on DNA biosynthesis in murine tumor models in vitro. Oncology (1987) 0.75
Antitumor effect of L-alanosine (NSC 153553) on sensitive and resistant sublines of murine leukemias. Tumori (1984) 0.75
Effect of hyperthermia alone and in combination with anticancer drugs on the viability of P388 leukemic cells. Tumori (1984) 0.75
In vitro modulation of adriamycin and mitoxantrone cytotoxicity by hyperthermia and diazepam, in human chronic myeloid leukemia cells. Neoplasma (1987) 0.75
Alteration in natural resistance of sarcoma 180 tumor to Bouvardin (NSC 259968) following hyperthermia. Tumori (1983) 0.75